Premium
Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1
Author(s) -
Kerl Kornelius,
Moreno Natalia,
Holsten Till,
Ahlfeld Julia,
Mertins Julius,
Hotfilder Marc,
Kool Marcel,
Bartelheim Kerstin,
Schleicher Sabine,
Handgretinger Rupert,
Schüller Ulrich,
Meisterernst Michael,
Frühwald Michael C.
Publication year - 2014
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.28719
Subject(s) - arsenic trioxide , gli1 , sonic hedgehog , cancer research , wnt signaling pathway , in vivo , hedgehog signaling pathway , in vitro , medulloblastoma , medicine , pathology , biology , apoptosis , signal transduction , microbiology and biotechnology , biochemistry
Rhabdoid tumors are highly aggressive tumors occurring in infants and very young children. Despite multimodal and intensive therapy prognosis remains poor. Molecular analyses have uncovered several deregulated pathways, among them the CDK4/6‐Rb‐, the WNT‐ and the Sonic hedgehog (SHH) pathways. The SHH pathway is activated in rhabdoid tumors by GLI1 overexpression. Here, we demonstrate that arsenic trioxide (ATO) inhibits tumor cell growth of malignant rhabdoid tumors in vitro and in a mouse xenograft model by suppressing Gli1. Our data uncover ATO as a promising therapeutic approach to improve prognosis for rhabdoid tumor patients.